EUVIMEDEUVIMED entdecken
Crossref

Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis

Dominika Ziolkowska-Banasik, Ewa Hadas, Maciej Pastuszczak

Journal of Drugs in Dermatology · 2024

DOI: 10.36849/jdd.7525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von Dominika Ziolkowska-Banasik und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Psoriasis, Biological Products, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsAntibodies, Monoclonal, HumanizedMaleHumansFemaleAntibodies, MonoclonalMonocytesTreatment OutcomeSeverity of Illness Index

Substanzen

secukinumabAntibodies, MonoclonalBiological ProductsAntibodies, Monoclonal, Humanized

Zitieren

APA

Ziolkowska-Banasik, D., Hadas, E., & Pastuszczak, M. (2024). Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7525

Vancouver

Ziolkowska-Banasik D, Hadas E, Pastuszczak M. Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7525

BibTeX
@article{ZiolkowskaBanasik2024,
  author = {Ziolkowska-Banasik, Dominika and Hadas, Ewa and Pastuszczak, Maciej},
  title = {Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  doi = {10.36849/jdd.7525}
}
Kostenlos starten →